Enhanced safety and efficacy of protease-regulated CAR-T cell receptors.
CAR-T therapy
T cell differentiation
T cell exhaustion
brain tumors
cellular immunotherapy
chimeric antigen receptors
immune cell engineering
solid cancers
synthetic biology
Journal
Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066
Informations de publication
Date de publication:
12 05 2022
12 05 2022
Historique:
received:
13
01
2021
revised:
04
01
2022
accepted:
29
03
2022
pubmed:
29
4
2022
medline:
18
5
2022
entrez:
28
4
2022
Statut:
ppublish
Résumé
Regulatable CAR platforms could circumvent toxicities associated with CAR-T therapy, but existing systems have shortcomings including leakiness and attenuated activity. Here, we present SNIP CARs, a protease-based platform for regulating CAR activity using an FDA-approved small molecule. Design iterations yielded CAR-T cells that manifest full functional capacity with drug and no leaky activity in the absence of drug. In numerous models, SNIP CAR-T cells were more potent than constitutive CAR-T cells and showed diminished T cell exhaustion and greater stemness. In a ROR1-based CAR lethality model, drug cessation following toxicity onset reversed toxicity, thereby credentialing the platform as a safety switch. In the same model, reduced drug dosing opened a therapeutic window that resulted in tumor eradication in the absence of toxicity. SNIP CARs enable remote tuning of CAR activity, which provides solutions to safety and efficacy barriers that are currently limiting progress in using CAR-T cells to treat solid tumors.
Identifiants
pubmed: 35483375
pii: S0092-8674(22)00391-9
doi: 10.1016/j.cell.2022.03.041
pmc: PMC9467936
mid: NIHMS1817780
pii:
doi:
Substances chimiques
Receptors, Antigen, T-Cell
0
Receptors, Chimeric Antigen
0
Peptide Hydrolases
EC 3.4.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1745-1763.e22Subventions
Organisme : NCI NIH HHS
ID : DP2 CA272092
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA260852
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA232568
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests L.L., R.G.M., M.Z.L., and C.L.M. are coinventors on a patent related to this work. C.L.M. is a cofounder of Lyell Immunopharma, Syncopation Life Sciences, and Link Cell Therapies, which are developing CAR-based therapies, and consults for Lyell, NeoImmune Tech, Apricity, Nektar, Immatics, Ensoma, Mammoth, Glaxo Smith Kline, and Bristol Myers Squibb. L.L., R.G.M., E.S., and E.W.W. are consultants for and hold equity in Lyell Immunopharma. L.L. is a cofounder of, consults for, and holds equity in Syncopation Life Sciences. R.G.M. is a cofounder of, consults for, and holds equity in Syncopation Life Sciences and Link Cell Therapies. R.G.M. is a consultant for Illumina Radiopharmaceuticals, NKarta, ImmunAI, Arovella Therapeutics, Zai Lab, and Aptorum Group. R.G.M. serves on the Data and Safety Monitoring Board for Fate Therapeutics. J.T. is a consultant for Dorian Therapeutics. E.W.W. consults for and holds equity in VISTAN Health. A.T.S. is a founder of Immunai and Cartography Biosciences and receives research funding from Arsenal Biosciences, Allogene Therapeutics, and 10x Genomics. K.R.P. is a cofounder and employee of Cartography Biosciences. H.Y.C. is a cofounder of Accent Therapeutics, Boundless Bio, and Cartography Biosciences and is an advisor to 10x Genomics, Arsenal Biosciences, and Spring Discovery. J.R.C. is a cofounder and equity holder of Trapeze Therapeutics, Combangio, and Virsti Therapeutics; he has financial interests in Aravive, Xyence Therapeutics, and Syncopation Life Sciences; and he is a member of the Board of Directors of Ligand Pharmaceuticals and Revel Pharmaceuticals. S.A.Y.-H. is a consultant for Trapeze Therapeutics and Xyence Therapeutics.
Références
Cells. 2020 May 09;9(5):
pubmed: 32397414
Nat Med. 2018 Jan;24(1):20-28
pubmed: 29155426
Nat Commun. 2018 Oct 22;9(1):4383
pubmed: 30348985
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Lancet. 2020 Dec 12;396(10266):1885-1894
pubmed: 33308471
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Clin Cancer Res. 2012 Dec 1;18(23):6436-45
pubmed: 23032741
Nat Med. 2015 Jun;21(6):581-90
pubmed: 25939063
Nature. 2020 Nov;587(7835):619-625
pubmed: 33208946
Cancer Cell. 2020 Oct 12;38(4):473-488
pubmed: 32735779
Cancer Immunol Res. 2016 Aug;4(8):658-68
pubmed: 27329987
Blood Adv. 2018 Mar 13;2(5):517-528
pubmed: 29507075
PLoS One. 2012;7(8):e44219
pubmed: 22937164
Bone Marrow Transplant. 2021 Mar;56(3):552-566
pubmed: 33230186
J Immunol. 2010 Jun 15;184(12):6756-65
pubmed: 20483739
Cancer Cell. 2019 Mar 18;35(3):489-503.e8
pubmed: 30889382
MAbs. 2019 May/Jun;11(4):621-631
pubmed: 30892136
Antimicrob Agents Chemother. 2019 Mar 27;63(4):
pubmed: 30745392
Cell. 2021 Dec 9;184(25):6081-6100.e26
pubmed: 34861191
Clin Cancer Res. 2018 Dec 15;24(24):6175-6184
pubmed: 30190371
Lancet. 2015 Feb 7;385(9967):517-528
pubmed: 25319501
Mol Ther. 2020 Jul 8;28(7):1600-1613
pubmed: 32559430
Cancer Res. 2020 Nov 1;80(21):4731-4740
pubmed: 32958548
J Immunother. 2005 May-Jun;28(3):203-11
pubmed: 15838376
Chem Biol. 2010 Sep 24;17(9):981-8
pubmed: 20851347
Mol Ther Methods Clin Dev. 2018 Jan 31;8:210-221
pubmed: 29552577
Oncotarget. 2017 Mar 7;8(10):17002-17011
pubmed: 28199983
Annu Rev Pharmacol Toxicol. 2016;56:59-83
pubmed: 26738472
CPT Pharmacometrics Syst Pharmacol. 2019 May;8(5):285-295
pubmed: 30848084
Nat Biotechnol. 2018 Apr;36(4):346-351
pubmed: 29505028
Annu Rev Immunol. 2020 Apr 26;38:123-145
pubmed: 32045313
BMC Biotechnol. 2019 Jul 3;19(1):44
pubmed: 31269942
Methods Mol Biol. 2014;1184:333-64
pubmed: 25048134
Nat Commun. 2020 Aug 20;11(1):4166
pubmed: 32820173
Annu Rev Med. 2014;65:405-15
pubmed: 24422576
Mol Ther. 2017 Mar 1;25(3):580-592
pubmed: 28187946
Genome Biol. 2019 Dec 23;20(1):296
pubmed: 31870423
Blood. 2016 Sep 29;128(13):1688-700
pubmed: 27412889
Nat Methods. 2020 Aug;17(8):852-860
pubmed: 32661427
Nat Commun. 2019 Nov 28;10(1):5415
pubmed: 31780669
Nature. 2017 Mar 2;543(7643):113-117
pubmed: 28225754
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 28947470
Front Med. 2017 Dec;11(4):554-562
pubmed: 28625015
Nat Biotechnol. 2020 Apr;38(4):426-432
pubmed: 32015549
Protein Cell. 2017 Sep;8(9):634-643
pubmed: 28434148
J Infect Dis. 2006 Dec 15;194(12):1724-8
pubmed: 17109345
JCI Insight. 2019 Apr 30;5:
pubmed: 31039141
PLoS One. 2013;8(3):e57838
pubmed: 23469246
Science. 2015 Oct 16;350(6258):aab4077
pubmed: 26405231
Genome Biol. 2019 Dec 31;21(1):1
pubmed: 31892341
Annu Rev Med. 2021 Jan 27;72:365-382
pubmed: 32776808
J Exp Med. 2004 Aug 2;200(3):307-19
pubmed: 15289502
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):14926-14935
pubmed: 32554495
Sci Signal. 2018 Aug 21;11(544):
pubmed: 30131370
Nat Med. 2018 Mar;24(3):352-359
pubmed: 29400710
Nat Med. 2019 Sep;25(9):1341-1355
pubmed: 31501612
Immunity. 2007 Oct;27(4):670-84
pubmed: 17950003
Front Immunol. 2018 Nov 08;9:2593
pubmed: 30467505
J Immunol. 2005 Sep 15;175(6):3603-13
pubmed: 16148104
Antivir Ther. 2008;13(4):481-94
pubmed: 18672527
Nat Chem Biol. 2015 Sep;11(9):713-20
pubmed: 26214256
Mol Ther. 2013 Apr;21(4):904-12
pubmed: 23423337
Immunity. 2001 Dec;15(6):883-95
pubmed: 11754811
Nat Med. 2021 Aug;27(8):1419-1431
pubmed: 34312556
Cancer Res. 2018 Aug 15;78(16):4692-4703
pubmed: 29967261
Semin Immunol. 1997 Dec;9(6):339-46
pubmed: 9405262
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Immunol Rev. 2019 Jul;290(1):39-59
pubmed: 31355492
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cytometry A. 2013 May;83(5):483-94
pubmed: 23512433
N Engl J Med. 2017 Dec 28;377(26):2545-2554
pubmed: 29226764
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Nat Methods. 2018 Jul;15(7):523-526
pubmed: 29967496
J Clin Oncol. 2018 Aug 1;36(22):2267-2280
pubmed: 29812997
Sci Adv. 2019 Dec 04;5(12):eaaw3851
pubmed: 31840053
Nat Methods. 2018 Jul;15(7):519-522
pubmed: 29967495
Hum Gene Ther. 2005 Apr;16(4):457-72
pubmed: 15871677
Nature. 2019 Dec;576(7786):293-300
pubmed: 31802004
Science. 2019 Sep 27;365(6460):1461-1466
pubmed: 31604275
Nat Biotechnol. 2016 Jul;34(7):760-7
pubmed: 27240196
Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):E459-68
pubmed: 26759369
J Immunol. 2015 Feb 15;194(4):2022-31
pubmed: 25609839
N Engl J Med. 2011 Nov 3;365(18):1673-83
pubmed: 22047558
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7788-E7797
pubmed: 27849617
N Engl J Med. 2019 May 2;380(18):1726-1737
pubmed: 31042825
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
Cancer Discov. 2017 Nov;7(11):1238-1247
pubmed: 28830878
J Biol Chem. 1993 Dec 15;268(35):26607-12
pubmed: 8253791
J Clin Invest. 2016 Nov 1;126(11):4262-4272
pubmed: 27760047
Nature. 2018 Oct;562(7727):367-372
pubmed: 30283141
Cancer Discov. 2017 Dec;7(12):1404-1419
pubmed: 29025771
Front Immunol. 2019 Apr 16;10:827
pubmed: 31057550
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Cancer Discov. 2020 May;10(5):702-723
pubmed: 32193224
Sci Transl Med. 2021 Jan 6;13(575):
pubmed: 33408186
Clin Cancer Res. 2019 Apr 15;25(8):2560-2574
pubmed: 30655315
Science. 2021 Apr 2;372(6537):
pubmed: 33795428
J Virol. 2000 Jul;74(14):6339-47
pubmed: 10864644
Cancer Immunol Immunother. 2017 Nov;66(11):1425-1436
pubmed: 28660319
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Nat Med. 2018 May;24(5):572-579
pubmed: 29662203
Antivir Ther. 2011;16(7):1093-102
pubmed: 22024525
Blood Adv. 2019 Mar 12;3(5):711-717
pubmed: 30814055
Cell. 2018 May 31;173(6):1426-1438.e11
pubmed: 29706540
PLoS One. 2017 Feb 7;12(2):e0171217
pubmed: 28170421
Lancet HIV. 2015 Aug;2(8):e319-27
pubmed: 26423374
Nat Biomed Eng. 2018 Jun;2(6):377-391
pubmed: 31011197
Front Immunol. 2019 Feb 15;10:218
pubmed: 30828333
Clin Cancer Res. 2020 Jun 1;26(11):2444-2451
pubmed: 32015021
Stat Biosci. 2020 Jul;12(2):146-166
pubmed: 33815623
J Immunother. 1998 Jan;21(1):75-83
pubmed: 9456440
Front Immunol. 2019 Jul 19;10:1691
pubmed: 31379876
Clin Cancer Res. 2013 Jun 15;19(12):3153-64
pubmed: 23620405
N Engl J Med. 2020 Apr 2;382(14):1331-1342
pubmed: 32242358
Nat Methods. 2013 May;10(5):407-9
pubmed: 23524392
Blood Rev. 2019 Mar;34:45-55
pubmed: 30528964
Blood. 2014 Aug 21;124(8):1277-87
pubmed: 24970931